Compare ResMed Inc. (RMD) vs ProShares Ultra Gold ETF (UGL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs ProShares Ultra Gold ETF — how do they compare? ResMed Inc. trades at $229.83 (market cap $31.89B), while ProShares Ultra Gold ETF trades at $46.27 (market cap $716.59M). The key difference: ResMed Inc. is far larger — about 44.5× ProShares Ultra Gold ETF's market cap, and ResMed Inc. pays a 1.16% dividend while ProShares Ultra Gold ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold ResMed Inc. for 51 Days and ProShares Ultra Gold ETF for 23 Days on average.
| RMD | UGL | |
|---|---|---|
Market Cap | $31.89B | $716.59M |
Volume | 618,314 | 2,592,878 |
Sector | Health | Leveraged / Inverse |
52-Week High | $277.88 | $85.62 |
52-Week Low | $182.82 | $42.79 |
Typical Hold Time | 51 Days | 23 Days |
Enterprise Value | $31.24B | — |
Dividend Yield | 1.16% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $228.37, up 1.06% today, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue grew to $5.15B in 2025, with a robust net income margin of 26.94%. Recent news highlights management's presentation at the Morgan Stanley Healthcare Conference and an upcoming Q1 2027 earnings report.
The outlook is positive, supported by earnings growth targets of 12-14% and a consensus price target of $242.70. Key risks include competitive pressures and ongoing legal investigations. Institutional buying activity and analyst upgrades reflect confidence, but investors should monitor execution against growth targets and any developments from the legal probe.
UGL trades at $46.24, up 4.07% today, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The stock faces resistance near $46 and support at $45. Financial ratios are unavailable, limiting fundamental assessment. Recent gold-related news highlights volatility from Treasury yields and Fed policy, influencing sentiment.
Outlook remains cautious due to bearish technicals and macroeconomic pressures. Risks include interest rate sensitivity and lack of financial transparency. Investors should await earnings reports for fundamental clarity amid current market uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About ProShares Ultra Gold ETF
UGL is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Bloomberg Gold Subindex. It is a tactical tool designed for sophisticated investors to magnify short-term bullish views on gold prices through the use of futures and swap contracts, rather than holding physical bullion.
Read more on UGL →
